“Global Biosimilars and Follow-On Biologics Drugs market set to grow to $14bn by 2024” says new Visiongain report

21 March 2019
Pharma

Visiongain has launched a new pharma report Global Biosimilars and Follow-On Biologics Market 2019-2029: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietins, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones.

Many companies are chasing development of the same biosimilar targets, which could lead to heavily fragmented markets if multiple therapies are approved. Although this occurs in the small molecule generics market, it will prove to be more of a challenge for biosimilars. There developers need to receive sufficient uptake to recoup the high development and manufacturing costs of biosimilars.

Uptake of biosimilars varies greatly between different regions, and marketing and education campaigns will be needed to combat this and convince consumers, doctors and healthcare payers of the benefits of biosimilars.

The lead analyst of the report commented "Growth will be restrained in the biosimilar growth hormones submarket by steady uptake for branded therapies, high brand loyalty, as well as the launch of long-acting growth hormones. Rising diabetes incidence will drive demand for biosimilar human insulin in emerging markets, while the launch of biosimilar insulin glargine in developed markets during the forecast period will drive growth in the biosimilar insulin analogues sector."

Leading companies featured in the report include Biocon Limited, Biogen Idec Inc., Bioton, Celltrion Pharm, Inc., Dong-A Pharmaceutical Co., Ltd., Dr.Reddy's Labs (DRL), Genentech (Roche Group), Hexal AG, Hospira, Intas Pharmaceuticals Ltd., LG Life Sciences and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever